Please assess the completion status of the following clinical trial:

Trial Title: TDENV PIV and LAV Dengue Prime-boost Strategy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female between 18 and 49 years of age (inclusive) at the time of consent~2. Able to provide written informed consent~3. Healthy as established by medical history and clinical examination before entering into the study~4. Able and willing to comply with the requirements of the protocol (eg, document events in memory aid, return for follow-up visits, etc.)~5. Female subject of non-childbearing potential (non-childbearing potential is defined as having either a current tubal ligation at least 3 months prior to enrollment or a history of a hysterectomy, ovariectomy, or is post-menopause)~6. Female subject is not breastfeeding and agrees not to breastfeed for 3 months after last vaccination~7. Female subject of childbearing potential may be enrolled in the study, if the subject has:~   1. Practiced adequate contraception for 30 days prior to vaccinations, and~  2. A negative urine pregnancy test on each day of vaccination, and~  3. Agreed to continue adequate contraception until 3 months after completion of the vaccination series.~Exclusion Criteria:~1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines during the period starting 30 days preceding the first dose of study vaccine and/or planned use during the study period~2. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 180 days prior to the first vaccine dose~   1. For corticosteroids, this will mean prednisone ≥ 20 mg/d or equivalent~  2. Inhaled and topical steroids are allowed~3. Planned administration or administration of a vaccine/product not foreseen by the study protocol during the period starting 14 days before or after each scheduled dose of an investigational product~4. Planned administration of any flavivirus vaccine for the entire study duration~5. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device)~6. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required)~7. Family history of congenital or hereditary immunodeficiency~8. History of, or current, auto-immune disease~9. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine or related to a study procedure~10. Major congenital defects or serious chronic illness~11. History of any neurological disorders or seizures. (except for a childhood febrile seizures)~12. Acute disease and/or fever (oral body temperature ≥ 100.4°F/38.0°C) at the time of enrollment (a subject with a minor illness, ie, mild diarrhea, mild upper respiratory infection, etc, without fever, may be enrolled at the discretion of the investigator)~13. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests~14. Administration of immunoglobulins and/or any blood products during the period starting 90 days preceding the first dose of study vaccine or planned administration during the study period~15. History of chronic alcohol and/or drug abuse~16. Pregnant or breastfeeding female or female planning to become pregnant or planning to discontinue contraceptive precautions~17. A planned move to a location that will prohibit participating in the trial prior to the study end for the participant~18. Subject seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV)~19. Safety laboratory test results that are outside the acceptable values at screening:~    1. \> 110% upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, creatinine, serum urea nitrogen (SUN) and bilirubin (total and direct)~   2. \< 100% lower limit of normal (LLN) or \> 120% ULN for hemoglobin, hematocrit and platelet count~   3. \< 75% LLN or \>110% ULN for total white blood cell count (WBC)~20. Any other condition which, in the opinion of the investigator, prevents the subject from participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: LAV (T=0), PIV (T=28) (Type: EXPERIMENTAL): Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 28 of the study.
- Group 2: PIV (T=0), LAV (T=28) (Type: EXPERIMENTAL): Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 28 of the study.
- Group 3: LAV (T=0), PIV (T=180) (Type: EXPERIMENTAL): Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 180 of the study.
- Group 4: PIV (T=0), LAV (T=180) (Type: EXPERIMENTAL): Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 180 of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete